Carlsmed, Inc. (NASDAQ:CARL) Given Average Rating of “Hold” by Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have earned a consensus rating of “Hold” from the five analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $21.3333.

CARL has been the topic of several research reports. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “sell (e-)” rating on shares of Carlsmed in a research report on Monday, December 22nd. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of Carlsmed in a research report on Friday, January 9th. Zacks Research lowered Carlsmed from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Finally, BTIG Research reissued a “buy” rating and issued a $24.00 price objective on shares of Carlsmed in a research note on Monday, December 15th.

Carlsmed Stock Up 4.1%

CARL stock opened at $10.40 on Tuesday. The stock’s 50 day simple moving average is $12.27 and its 200 day simple moving average is $13.03. The company has a market cap of $277.99 million and a P/E ratio of -2.84. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.74 and a current ratio of 8.87. Carlsmed has a fifty-two week low of $9.80 and a fifty-two week high of $17.19.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.11. Carlsmed had a negative return on equity of 72.60% and a negative net margin of 58.67%.The firm had revenue of $15.16 million during the quarter, compared to the consensus estimate of $15.20 million.

Hedge Funds Weigh In On Carlsmed

A number of hedge funds have recently bought and sold shares of CARL. BNP Paribas Financial Markets purchased a new stake in shares of Carlsmed in the third quarter valued at about $33,000. JPMorgan Chase & Co. purchased a new position in Carlsmed during the third quarter worth about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Carlsmed in the 3rd quarter worth about $42,000. Rhumbline Advisers purchased a new stake in Carlsmed in the 3rd quarter valued at about $79,000. Finally, Wells Fargo & Company MN lifted its position in shares of Carlsmed by 61.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after buying an additional 2,989 shares in the last quarter.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).